Strata Critical Medical (SRTA) Jefferies Mining and Industrials Conference 2025 summary

Transaction overview and strategic shift

• Sold passenger business to Joby Aviation for up to $125M, with $80M received in Joby stock and the remainder as holdback and earn-out.

• Retained long-term access to rotorcraft and future Joby eVTOLs for medical use, enhancing service flexibility and cost efficiency.

• Transition enables exclusive focus on the medical segment, which is the fastest-growing and most profitable area.

• Divestiture expected to be profit neutral, with $7M in annual corporate cost savings starting Q4.

• Capital from the sale will be reinvested in expanding medical logistics and exploring adjacent time-critical markets.

Medical logistics business and market dynamics

• Operates one of the largest U.S. organ transport networks, using an asset-light model with a mix of owned and third-party aircraft.

• Regulatory changes and new technology are increasing the number and distance of organ transplants, driving demand for flexible logistics.

• Growth in perfusion technology allows more organs to be used, supporting mid to high single-digit market growth.

• Average donor-recipient distance has risen 50% in five years, increasing flight hours and complexity.

• Expanded into ground transport and administrative services, with opportunities to internalize more of the logistics chain.

Competitive landscape and growth strategy

• Holds about 30% share in air organ transport, with single-digit share in ancillary services.

• Competes against fragmented, local operators; national network and flexible fleet provide a competitive edge.

• Customer acquisition often occurs when legacy providers cannot meet complex or urgent needs.

• Strategic partnerships, such as with OrganOx, position the company to lead in new in-flight perfusion capabilities.

• Plans to grow both organically and through acquisitions, targeting both core and adjacent markets.